A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia (VascDem)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00947531 |
|
Recruitment Status :
Completed
First Posted : July 28, 2009
Results First Posted : July 28, 2009
Last Update Posted : August 3, 2020
|
Sponsor:
Ever Neuro Pharma GmbH
Collaborators:
acromion GmbH
Geny Research Corp.
Information provided by:
Ever Neuro Pharma GmbH
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This clinical trial was performed to assess the clinical efficacy and safety of two 4 week treatment courses of daily intravenous administration of Cerebrolysin (20mL [milliliter] IV [intravenous] per day). The study was performed as prospective, randomised, double-blind, placebo-controlled, parallel group, multicentre study with 2 study groups.
Group 1: 20 mL Cerebrolysin and 100 mg (milligram) acetylsalicylic acid Group 2: Placebo (0.9% NaCl [sodium chloride]) and 100 mg acetylsalicylic acid The study drug was given once daily by intravenous infusion (20ml in 250ml saline solution) for 4 weeks on five consecutive days per week. This treatment regimen was repeated after a two-month treatment-free interval. Acetylsalicylic acid was given orally, once daily throughout the study duration of 24 weeks.
Altogether five clinical evaluation visits at Baseline (day 0) and at week 4, 12, 16, and 24 were necessary.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Vascular Dementia | Drug: Cerebrolysin Drug: 0.9% Saline Solution | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 242 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia |
| Study Start Date : | October 2006 |
| Actual Study Completion Date : | August 2007 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Cerebrolysin |
Drug: Cerebrolysin |
| Placebo Comparator: 0.9% Saline Solution |
Drug: 0.9% Saline Solution |
Primary Outcome Measures :
- Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24 [ Time Frame: baseline and week 24 ]The ADAS-COG+ is a psychometric instrument used to evaluate memory, attention, reasoning, language, orientation and praxis. The score ranges from 0 to 85 with 85 being the worst score. A negative change indicates cognitive improvement.
- CIBIC+ (Clinicians Interview-based Impression of Change) Score at Week 24 [ Time Frame: week 24 ]This rating scale is based on the health care provider's "general clinical impressions" with the informant input (i.e. family members). It evaluates global function and is scored from 1 (marked improvement) to 7 (marked worsening).
Secondary Outcome Measures :
- Change From Baseline in ADAS-COG+ (Alzheimer's Disease Assessment Scale Cognitive Subpart) [ Time Frame: week 4, 12, 16 ]The modified Alzheimer's Disease Assessment Scale - Cognitive (ADAS-COG+) is a psychometric instrument used by a neuropsychologist that evaluates memory, attention, reasoning, language, orientation and praxis.
- ADAS-COG+ Response [ Time Frame: week 4, 12, 16, 24 ]A patient with an improvement from baseline of ≥ 4 points in the ADAS-COG+ score at a particular visit is considered to have an ADAS-COG+ response at that visit.
- Change From Baseline for Original ADAS-COG [ Time Frame: week 4, 12, 16, 24 ]The Original Alzheimer's Disease Assessment Scale - Cognitive (ADAS-COG) is comprised of items 1-11 of the modified ADAS-COG+.
- CIBIC+ Score [ Time Frame: week 4, 12, 16 ]The Clinician Interview-based Impression of Change (CIBIC+) score is assigned by an experienced physician familiar with the manifestations of dementia after interviewing the patient and the caregiver.
- CIBIC+ Response [ Time Frame: week 4, 12, 16, 24 ]A patient with a CIBIC+ score of 1 to 3 at a particular visit is considered to have a CIBIC+ response at that visit. Patients with a score of 0, indicating that the assessment was not performed, are considered to be non-responders.
- CIBIS+ (Clinicians Interview-Based Impression of Severity) [ Time Frame: week 24 ]The Clinician Interview-based Impression of Disease Severity (CIBIS+) score is assigned by an experienced physician, familiar with the manifestations of dementia, after interviewing the patient and the caregiver.
- Change From Baseline in MMSE (Mini-Mental State Examination) Score [ Time Frame: week 4, 12, 16, 24 ]The Mini-Mental State Examination (MMSE) is a frequently used screening instrument for clinical trials conducted in patients with Alzheimer's Disease. It evaluates orientation, registration, attention and calculation, recall and language.
- Change From Baseline in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale) [ Time Frame: week 4, 12, 16, 24 ]The ADCS-ADL is a measure of functional disability. The ADCS-ADL assessment of activities of daily living is based on an interview with the caregiver.
- Change From Baseline in Trail-making Test [ Time Frame: week 4, 12, 16, 24 ]The Trail-making test is a frequently used instrument for the assessment of executive function.
- Change From Baseline in Clock-drawing Test [ Time Frame: week 4, 12, 16, 24 ]The Clock-drawing test is a frequently used screening instrument for dementia drug studies. It evaluates executive function of demented patients.
- Combined Response, i.e. Response in ADAS-COG+ and CIBIC+ [ Time Frame: week 4, 12, 16, 24 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 50 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Men or post-menopausal women between 50 and 85 years
- Clinical diagnosis of vascular dementia according to NINDS-AIREN criteria
- CT or MRI results compatible with clinical diagnosis
- MMSE score between 10 and 24, both inclusive
- Modified Hachinski Ischemic Score >4
- Hamilton Depression Scale score of less than or equal to 15
- Adequate visual and auditory acuity to allow neuropsychological testing
- Informed consent given by the patient and/or the next-of-kin
Exclusion Criteria:
- Gastric ulcer associated with intolerance of acetylsalicylic acid treatment
- Severe psychotic features, schizophrenia, depression, agitation or behavioral problems within the last three months that could lead to difficulty complying with the protocol
- Any severe systemic illness or unstable medical condition that could lead to difficulty complying with the protocol or significantly limits life span.
- Patients who in the investigator's opinion, would not comply with study procedures
- Any significant neurological disease other than vascular dementia, such as Parkinson's disease, epilepsy, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis
- History of alcohol or substance abuse or dependence within the past two years
- Patients with a history of systemic cancer within the past two years
- Severe congestive heart failure or malignant, uncontrollable hypertension
- Participation in a clinical trial with an investigational drug in the past four weeks
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00947531
Locations
Show 21 study locations
Sponsors and Collaborators
Ever Neuro Pharma GmbH
acromion GmbH
Geny Research Corp.
Investigators
| Study Director: | Philipp Novak, PhD | EBEWE Neuro Pharma |
| Responsible Party: | Philipp Novak, PhD, EBEWE Neuro Pharma |
| ClinicalTrials.gov Identifier: | NCT00947531 |
| Other Study ID Numbers: |
EBE-RU-051201 |
| First Posted: | July 28, 2009 Key Record Dates |
| Results First Posted: | July 28, 2009 |
| Last Update Posted: | August 3, 2020 |
| Last Verified: | July 2020 |
Additional relevant MeSH terms:
|
Dementia Dementia, Vascular Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurocognitive Disorders Mental Disorders Cerebrovascular Disorders Intracranial Arteriosclerosis Intracranial Arterial Diseases |
Leukoencephalopathies Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Cerebrolysin Neuroprotective Agents Protective Agents Physiological Effects of Drugs Nootropic Agents |